These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 7718674)

  • 21. Endocrine and hemodynamic effects of stress versus systemic CRF in alcoholics during early and medium term abstinence.
    Ehrenreich H; Schuck J; Stender N; Pilz J; Gefeller O; Schilling L; Poser W; Kaw S
    Alcohol Clin Exp Res; 1997 Oct; 21(7):1285-93. PubMed ID: 9347091
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Behavioural effects of rapid intravenous administration of meta-chlorophenylpiperazine in patients with panic disorder and controls.
    van der Wee NJ; Fiselier J; van Megen HJ; Westenberg HG
    Eur Neuropsychopharmacol; 2004 Oct; 14(5):413-7. PubMed ID: 15336303
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Nocturnal panic: biology, psychopathology, and its contribution to the expression of panic disorder.
    Merritt-Davis O; Balon R
    Depress Anxiety; 2003; 18(4):221-7. PubMed ID: 14661192
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Prolactin response to dl-fenfluramine in panic disorder.
    Apostolopoulos M; Judd FK; Burrows GD; Norman TR
    Psychoneuroendocrinology; 1993; 18(5-6):337-42. PubMed ID: 8416044
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Behavioral indications for serotonin receptor hypersensitivity in panic disorder.
    Kahn RS; Wetzler S; van Praag HM; Asnis GM; Strauman T
    Psychiatry Res; 1988 Jul; 25(1):101-4. PubMed ID: 3217461
    [TBL] [Abstract][Full Text] [Related]  

  • 26. 5-HT1A responsivity in patients with panic disorder before and after treatment with aerobic exercise, clomipramine or placebo.
    Broocks A; Meyer T; Opitz M; Bartmann U; Hillmer-Vogel U; George A; Pekrun G; Wedekind D; Rüther E; Bandelow B
    Eur Neuropsychopharmacol; 2003 May; 13(3):153-64. PubMed ID: 12729940
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Behavioral and neuroendocrine responses to m-chlorophenylpiperazine in subtypes of alcoholics and in healthy comparison subjects.
    George DT; Benkelfat C; Rawlings RR; Eckardt MJ; Phillips MJ; Nutt DJ; Wynne D; Murphy DL; Linnoila M
    Am J Psychiatry; 1997 Jan; 154(1):81-7. PubMed ID: 8988963
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Antidepressants in panic disorder: clinical and preclinical mechanisms.
    Nutt DJ
    J Clin Psychiatry; 1998; 59 Suppl 8():24-8; discussion 29. PubMed ID: 9707159
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Pituitary hormone responses to meta-chlorophenylpiperazine in panic disorder and healthy control subjects.
    Kahn RS; Wetzler S; Asnis GM; Kling MA; Suckow RF; van Praag HM
    Psychiatry Res; 1991 Apr; 37(1):25-34. PubMed ID: 1650487
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Serotonergic and noradrenergic dysregulation in alcoholism: m-chlorophenylpiperazine and yohimbine effects in recently detoxified alcoholics and healthy comparison subjects.
    Krystal JH; Webb E; Cooney NL; Kranzler HR; Southwick SW; Heninger GR; Charney DS
    Am J Psychiatry; 1996 Jan; 153(1):83-92. PubMed ID: 8540598
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The mechanisms of action of lithium. I. Effects on serotoninergic and noradrenergic systems in normal subjects.
    Manji HK; Hsiao JK; Risby ED; Oliver J; Rudorfer MV; Potter WZ
    Arch Gen Psychiatry; 1991 Jun; 48(6):505-12. PubMed ID: 1645513
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Neuroendocrine evidence for reduced serotonergic neurotransmission during heavy drinking.
    Balldin J; Berggren U; Engel J; Eriksson M
    Alcohol Clin Exp Res; 1994 Aug; 18(4):822-5. PubMed ID: 7978090
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Pentagastrin infusions in patients with panic disorder. II. Neuroendocrinology.
    Abelson JL; Nesse RM; Vinik AI
    Biol Psychiatry; 1994 Jul; 36(2):84-96. PubMed ID: 7524696
    [TBL] [Abstract][Full Text] [Related]  

  • 34. 5-HT1A receptor-effector system responsivity in panic disorder.
    Lesch KP; Wiesmann M; Hoh A; Müller T; Disselkamp-Tietze J; Osterheider M; Schulte HM
    Psychopharmacology (Berl); 1992; 106(1):111-7. PubMed ID: 1346719
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Smoking modulates neuroendocrine responses to ipsapirone in patients with panic disorder.
    Broocks A; Bandelow B; Koch K; Bartmann U; Kinkelbur J; Schweiger U; Hohagen F; Hajak G
    Neuropsychopharmacology; 2002 Aug; 27(2):270-8. PubMed ID: 12093600
    [TBL] [Abstract][Full Text] [Related]  

  • 36. m-Chlorophenylpiperazine as a probe of serotonin function.
    Kahn RS; Wetzler S
    Biol Psychiatry; 1991 Dec; 30(11):1139-66. PubMed ID: 1663792
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Effects of the serotonin reuptake inhibitor fluvoxamine on yohimbine-induced anxiety in panic disorder.
    Goddard AW; Woods SW; Sholomskas DE; Goodman WK; Charney DS; Heninger GR
    Psychiatry Res; 1993 Aug; 48(2):119-33. PubMed ID: 8416022
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Prolactin but not ACTH increases during sodium lactate-induced panic attacks.
    Otte C; Kellner M; Arlt J; Jahn H; Holsboer F; Wiedemann K
    Psychiatry Res; 2002 Mar; 109(2):201-5. PubMed ID: 11927145
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Endocrine, cardiovascular, and behavioral responses to clonidine in patients with panic disorder.
    Abelson JL; Glitz D; Cameron OG; Lee MA; Bronzo M; Curtis GC
    Biol Psychiatry; 1992 Jul; 32(1):18-25. PubMed ID: 1391293
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Abnormal neuroendocrine response to clomipramine in hereditary affective psychosis.
    Cordes J; Larisch R; Henning U; Thünker J; Werner C; Orozco G; Mayoral F; Rivas F; Auburger G; Tosch M; Rietschel M; Gaebel W; Müller HW; Klimke A
    Depress Anxiety; 2009; 26(8):E111-9. PubMed ID: 19288582
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.